Last week was one to forget for the Pfizer campaign team, which at times appeared to have adopted the Millwall strategy of no one likes us, we don’t care.
This week, Read’s two-day charm offensive is designed to focus on the size of its research facilities, not the size of its wallet.
Questions remain about Pfizer’s use of Britain as a handy tax shelter. Whether its commitments to Cambridge and jobs are legally binding is not the point. Five years is a skimpy promise when you consider AstraZeneca’s decades of heritage.
And what happens if Pfizer is carved into three somewhere down the line, a move seen by some as Read’s crowning glory?
